Gene involved in pulmonary hypertension is identified
This article was originally published in Clinica
Executive Summary
Two groups of researchers based mainly in the US claim to have discovered a link between mutations in the bone morphogenetic protein receptor type II (BMPR2) gene and the rare condition, primary pulmonary hypertension (PPH). The main pathogenic feature of this fatal condition is obstruction of the pulmonary arterioles caused by proliferation of endothelial cells, which leads to elevated pressure in the pulmonary artery and right ventricular failure.
You may also be interested in...
News We’re Watching: AI Safety Partnership; Boston Scientific Recalls; New Cancer, STI Tests; VR
This week, the US and UK announced a partnership to promote AI safety. Boston Scientific recalls embolic agent. LumiCell received FDA approval for its imaging agent to detect residual cancer. Scout receives an award to develop an STI test; and Osso VR leverages the Apple Vision Pro for VR medical training.
Finance Watch: Canaan, Regeneron Reveal New Funds For Start-Ups
Private Company Edition: Regeneron launched a $500m venture fund and Canaan added $100m, bringing the venture firm’s recent total to $1bn-plus. Also, incubators plan to grow over the next decade and in recent financings Avenzo raised $150m and Nvelop launched with $100m.
Pink Sheet Podcast: Leqembi Spending, Woodcock’s Next Act, Pneumococcal Vaccine Development
Pink Sheet editors discuss Medicare spending projections for the Alzheimer’s treatment Leqembi, Janet Woodcock’s new post-FDA role, and ongoing preparations for new pneumococcal vaccines that will reach the market soon.